Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-09

AUTHORS

Joseph Proietto, Jaret Malloy, Dongliang Zhuang, Mark Arya, Neale D. Cohen, Ferdinandus J. de Looze, Christopher Gilfillan, Paul Griffin, Stephen Hall, Thomas Nathow, Geoffrey S. Oldfield, David N. O’Neal, Adam Roberts, Bronwyn G. A. Stuckey, Dennis Yue, Kristin Taylor, Dennis Kim

ABSTRACT

AIMS/HYPOTHESIS: This multicentre randomised double-blind placebo-controlled clinical trial assessed the efficacy and safety of a methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib, in individuals with obesity (BMI ≥30 kg/m2) and type 2 diabetes (HbA1c 53-97 mmol/mol [7-11%] and fasting glucose <15.6 mmol/l). METHODS: Participants were randomised (via a centralised interactive web response system) to placebo, 1.2 or 1.8 mg beloranib s.c. twice weekly for 26 weeks. Participants, investigators and the sponsor were blinded to group assignment. The primary endpoint was the change in weight from baseline to week 26. The trial was terminated early when beloranib development was stopped because of an imbalance of venous thromboembolism events in beloranib-treated individuals vs placebo that became evident during late-stage development of the drug. RESULTS: In total, 153 participants were randomised, 51 to placebo, 52 to 1.2 mg beloranib and 50 to 1.8 mg beloranib. In participants who completed week 26, the least squares mean ± SE weight change (baseline 111 kg) was -3.1 ± 1.2% with placebo (n = 22) vs -13.5 ± 1.1% and -12.7 ± 1.3% with 1.2 and 1.8 mg beloranib, respectively (n = 25; n = 19; p < 0.0001). The change in HbA1c (baseline 67 mmol/mol [8.3%]) was -6.6 ± 2.2 mmol/mol (-0.6 ± 0.2%) with placebo vs -21.9 ± 2.2 mmol/mol (-2.0 ± 0.2%) or -21.9 ± 3.3 mmol/mol (-2.0 ± 0.3%) with 1.2 or 1.8 mg beloranib (p < 0.0001), respectively. The most common beloranib adverse events were sleep related. One beloranib-treated participant experienced a non-fatal pulmonary embolism. CONCLUSIONS/INTERPRETATION: MetAP2 inhibitors represent a novel mechanism for producing meaningful weight loss and improvement in HbA1c. TRIAL REGISTRATION: ClinicalTrials.gov NCT02324491 FUNDING: The study was funded by Zafgen, Inc. More... »

PAGES

1918-1922

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-018-4677-0

DOI

http://dx.doi.org/10.1007/s00125-018-4677-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105454719

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29992370


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Melbourne", 
          "id": "https://www.grid.ac/institutes/grid.1008.9", 
          "name": [
            "Department of Medicine (Austin Health), University of Melbourne, Heidelberg, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Proietto", 
        "givenName": "Joseph", 
        "id": "sg:person.01051662137.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051662137.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zafgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.476821.e", 
          "name": [
            "Zafgen, Inc., 175 Portland St, 4th Floor, 02114, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malloy", 
        "givenName": "Jaret", 
        "id": "sg:person.0722737420.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722737420.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zafgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.476821.e", 
          "name": [
            "Zafgen, Inc., 175 Portland St, 4th Floor, 02114, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhuang", 
        "givenName": "Dongliang", 
        "id": "sg:person.0576721137.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576721137.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Australian Clinical Research Network, Maroubra, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arya", 
        "givenName": "Mark", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baker IDI Heart and Diabetes Institute", 
          "id": "https://www.grid.ac/institutes/grid.1051.5", 
          "name": [
            "Baker Heart and Diabetes Institute, Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cohen", 
        "givenName": "Neale D.", 
        "id": "sg:person.01323317216.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323317216.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Queensland", 
          "id": "https://www.grid.ac/institutes/grid.1003.2", 
          "name": [
            "AusTrials Pty Ltd, Sherwood, QLD, Australia", 
            "Discipline of General Practice, Faculty of Medicine, University of Queensland, Herston, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Looze", 
        "givenName": "Ferdinandus J.", 
        "id": "sg:person.01007616347.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007616347.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Monash University", 
          "id": "https://www.grid.ac/institutes/grid.1002.3", 
          "name": [
            "Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilfillan", 
        "givenName": "Christopher", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Queensland", 
          "id": "https://www.grid.ac/institutes/grid.1003.2", 
          "name": [
            "Q-Pharm Pty Ltd, Herston, QLD, Australia", 
            "QIMR Berghofer Medical Research Institute, Herston, QLD, Australia", 
            "Mater Health Services, South Brisbane, QLD, Australia", 
            "Faculty of Medicine, University of Queensland, Herston, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Griffin", 
        "givenName": "Paul", 
        "id": "sg:person.01052333026.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052333026.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Monash University", 
          "id": "https://www.grid.ac/institutes/grid.1002.3", 
          "name": [
            "Emeritus Research, Malvern East, VIC, Australia", 
            "Institution for Rehabilitation Research, Monash University, Clayton, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hall", 
        "givenName": "Stephen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ipswich Research Institute, Ipswich, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nathow", 
        "givenName": "Thomas", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pendlebury Research, Cardiff, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oldfield", 
        "givenName": "Geoffrey S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medicine, University of Melbourne, St Vincent\u2019s Hospital, Fitzroy, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Neal", 
        "givenName": "David N.", 
        "id": "sg:person.01325205777.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325205777.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geelong Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415335.5", 
          "name": [
            "University Hospital Geelong, Geelong, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roberts", 
        "givenName": "Adam", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Keogh Institute for Medical Research", 
          "id": "https://www.grid.ac/institutes/grid.489043.2", 
          "name": [
            "Keogh Institute for Medical Research, University of Western Australia, Nedlands, WA, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stuckey", 
        "givenName": "Bronwyn G. A.", 
        "id": "sg:person.01123267045.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123267045.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Prince Alfred Hospital", 
          "id": "https://www.grid.ac/institutes/grid.413249.9", 
          "name": [
            "Royal Prince Alfred Hospital, Camperdown, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yue", 
        "givenName": "Dennis", 
        "id": "sg:person.012621644022.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012621644022.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zafgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.476821.e", 
          "name": [
            "Zafgen, Inc., 175 Portland St, 4th Floor, 02114, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taylor", 
        "givenName": "Kristin", 
        "id": "sg:person.014420273662.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014420273662.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Zafgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.476821.e", 
          "name": [
            "Zafgen, Inc., 175 Portland St, 4th Floor, 02114, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Dennis", 
        "id": "sg:person.011171643560.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011171643560.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3389/fendo.2013.00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001416282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005353201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/oby.20356", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016812973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1677/jme.1.02165", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041136245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.162349799", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042637853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi049172p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055199593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi049172p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055199593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12928", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084211943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085714853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085714853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085714853"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)33102-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099600682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/jpet.117.246272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101276712"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-09", 
    "datePublishedReg": "2018-09-01", 
    "description": "AIMS/HYPOTHESIS: This multicentre randomised double-blind placebo-controlled clinical trial assessed the efficacy and safety of a methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib, in individuals with obesity (BMI \u226530\u00a0kg/m2) and type 2 diabetes (HbA1c 53-97\u00a0mmol/mol [7-11%] and fasting glucose <15.6\u00a0mmol/l).\nMETHODS: Participants were randomised (via a centralised interactive web response system) to placebo, 1.2 or 1.8\u00a0mg beloranib s.c. twice weekly for 26\u00a0weeks. Participants, investigators and the sponsor were blinded to group assignment. The primary endpoint was the change in weight from baseline to week 26. The trial was terminated early when beloranib development was stopped because of an imbalance of venous thromboembolism events in beloranib-treated individuals vs placebo that became evident during late-stage development of the drug.\nRESULTS: In total, 153 participants were randomised, 51 to placebo, 52 to 1.2\u00a0mg beloranib and 50 to 1.8\u00a0mg beloranib. In participants who completed week 26, the least squares mean \u00b1 SE weight change (baseline 111\u00a0kg) was -3.1\u2009\u00b1\u20091.2% with placebo (n\u2009=\u200922) vs -13.5\u2009\u00b1\u20091.1% and -12.7\u2009\u00b1\u20091.3% with 1.2 and 1.8\u00a0mg beloranib, respectively (n\u2009=\u200925; n\u2009=\u200919; p\u2009<\u20090.0001). The change in HbA1c (baseline 67\u00a0mmol/mol [8.3%]) was -6.6\u2009\u00b1\u20092.2\u00a0mmol/mol (-0.6\u2009\u00b1\u20090.2%) with placebo vs -21.9\u2009\u00b1\u20092.2\u00a0mmol/mol (-2.0\u2009\u00b1\u20090.2%) or -21.9\u2009\u00b1\u20093.3\u00a0mmol/mol (-2.0\u2009\u00b1\u20090.3%) with 1.2 or 1.8\u00a0mg beloranib (p\u2009<\u20090.0001), respectively. The most common beloranib adverse events were sleep related. One beloranib-treated participant experienced a non-fatal pulmonary embolism.\nCONCLUSIONS/INTERPRETATION: MetAP2 inhibitors represent a novel mechanism for producing meaningful weight loss and improvement in HbA1c.\nTRIAL REGISTRATION: ClinicalTrials.gov NCT02324491 FUNDING: The study was funded by Zafgen, Inc.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00125-018-4677-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "61"
      }
    ], 
    "name": "Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial", 
    "pagination": "1918-1922", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "49b698348c027d38ce2ab4468c48af90d39835147582f779bd0acf4b2a35c32c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29992370"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0006777"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-018-4677-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105454719"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-018-4677-0", 
      "https://app.dimensions.ai/details/publication/pub.1105454719"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000353_0000000353/records_45366_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00125-018-4677-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-018-4677-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-018-4677-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-018-4677-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-018-4677-0'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      39 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-018-4677-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4f67a59f0fcd46eb8f8a47384137f85c
4 schema:citation https://doi.org/10.1002/oby.20356
5 https://doi.org/10.1016/s0140-6736(17)33102-1
6 https://doi.org/10.1021/bi049172p
7 https://doi.org/10.1073/pnas.162349799
8 https://doi.org/10.1111/dom.12457
9 https://doi.org/10.1111/dom.12928
10 https://doi.org/10.1111/dom.13021
11 https://doi.org/10.1124/jpet.117.246272
12 https://doi.org/10.1677/jme.1.02165
13 https://doi.org/10.3389/fendo.2013.00001
14 schema:datePublished 2018-09
15 schema:datePublishedReg 2018-09-01
16 schema:description AIMS/HYPOTHESIS: This multicentre randomised double-blind placebo-controlled clinical trial assessed the efficacy and safety of a methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib, in individuals with obesity (BMI ≥30 kg/m2) and type 2 diabetes (HbA1c 53-97 mmol/mol [7-11%] and fasting glucose <15.6 mmol/l). METHODS: Participants were randomised (via a centralised interactive web response system) to placebo, 1.2 or 1.8 mg beloranib s.c. twice weekly for 26 weeks. Participants, investigators and the sponsor were blinded to group assignment. The primary endpoint was the change in weight from baseline to week 26. The trial was terminated early when beloranib development was stopped because of an imbalance of venous thromboembolism events in beloranib-treated individuals vs placebo that became evident during late-stage development of the drug. RESULTS: In total, 153 participants were randomised, 51 to placebo, 52 to 1.2 mg beloranib and 50 to 1.8 mg beloranib. In participants who completed week 26, the least squares mean ± SE weight change (baseline 111 kg) was -3.1 ± 1.2% with placebo (n = 22) vs -13.5 ± 1.1% and -12.7 ± 1.3% with 1.2 and 1.8 mg beloranib, respectively (n = 25; n = 19; p < 0.0001). The change in HbA1c (baseline 67 mmol/mol [8.3%]) was -6.6 ± 2.2 mmol/mol (-0.6 ± 0.2%) with placebo vs -21.9 ± 2.2 mmol/mol (-2.0 ± 0.2%) or -21.9 ± 3.3 mmol/mol (-2.0 ± 0.3%) with 1.2 or 1.8 mg beloranib (p < 0.0001), respectively. The most common beloranib adverse events were sleep related. One beloranib-treated participant experienced a non-fatal pulmonary embolism. CONCLUSIONS/INTERPRETATION: MetAP2 inhibitors represent a novel mechanism for producing meaningful weight loss and improvement in HbA1c. TRIAL REGISTRATION: ClinicalTrials.gov NCT02324491 FUNDING: The study was funded by Zafgen, Inc.
17 schema:genre research_article
18 schema:inLanguage en
19 schema:isAccessibleForFree true
20 schema:isPartOf Nb3e6cfd1c1594f3fa2167cc7c4ccc8df
21 Ncf0dbbb0088f46a3a38a9d884a72f47a
22 sg:journal.1001482
23 schema:name Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial
24 schema:pagination 1918-1922
25 schema:productId N0d64b934b4d240c3b1394c30bc93fd00
26 N194190f5d35740d1a55be8ec60fdba6c
27 N5ced31c17576452faf6bfbdb6d84025e
28 Nbfa2c6b101634ab2a2d25d8fd4abe26d
29 Ndf3b5ab39be74d72b1a0e96db6a91d89
30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105454719
31 https://doi.org/10.1007/s00125-018-4677-0
32 schema:sdDatePublished 2019-04-11T11:13
33 schema:sdLicense https://scigraph.springernature.com/explorer/license/
34 schema:sdPublisher N2b62341a70a34736af10f9708083dc44
35 schema:url http://link.springer.com/10.1007%2Fs00125-018-4677-0
36 sgo:license sg:explorer/license/
37 sgo:sdDataset articles
38 rdf:type schema:ScholarlyArticle
39 N0214cbad49f14eb1b6a458c1510e62fb schema:name Department of Medicine, University of Melbourne, St Vincent’s Hospital, Fitzroy, VIC, Australia
40 rdf:type schema:Organization
41 N0ce7fc39edaa4862805dc28b41454684 rdf:first sg:person.014420273662.55
42 rdf:rest N16f4fe5b23c24b60b9d82fbd903b74f1
43 N0d64b934b4d240c3b1394c30bc93fd00 schema:name readcube_id
44 schema:value 49b698348c027d38ce2ab4468c48af90d39835147582f779bd0acf4b2a35c32c
45 rdf:type schema:PropertyValue
46 N16f4fe5b23c24b60b9d82fbd903b74f1 rdf:first sg:person.011171643560.46
47 rdf:rest rdf:nil
48 N194190f5d35740d1a55be8ec60fdba6c schema:name pubmed_id
49 schema:value 29992370
50 rdf:type schema:PropertyValue
51 N1f201c7333b444b79453bf6d3e4981f2 schema:name Pendlebury Research, Cardiff, NSW, Australia
52 rdf:type schema:Organization
53 N2b62341a70a34736af10f9708083dc44 schema:name Springer Nature - SN SciGraph project
54 rdf:type schema:Organization
55 N2c8a4c3d0ac643fab4b1cfd5f32dcac7 schema:affiliation https://www.grid.ac/institutes/grid.1002.3
56 schema:familyName Hall
57 schema:givenName Stephen
58 rdf:type schema:Person
59 N2dcff7f4309c457b9602107eba893ea6 rdf:first sg:person.0576721137.94
60 rdf:rest Nc627e33c26e44e1094a36768638096da
61 N303a87b1a0944f95bc715c642ca843c7 rdf:first Nfaa313501f06445191b285ff59dfcb7f
62 rdf:rest N81ff66dbca2a4f3f953e05f91764997f
63 N30ad39668f714e569948414d43c7e404 schema:affiliation Nd9f65af247c94be292ac8564e38defbf
64 schema:familyName Arya
65 schema:givenName Mark
66 rdf:type schema:Person
67 N32528bcf930f4217a37f31a318149a14 rdf:first sg:person.01007616347.53
68 rdf:rest Nf9f8cb595d534931855c34c90502b7fc
69 N34cb7fff3f094efab0a26fe2c7309dcf rdf:first sg:person.0722737420.82
70 rdf:rest N2dcff7f4309c457b9602107eba893ea6
71 N38b66a4934a34cd2ad78fd70b112d0f3 rdf:first sg:person.012621644022.25
72 rdf:rest N0ce7fc39edaa4862805dc28b41454684
73 N3ebd7f5d1f3d4b2b9b9e3ea594e8d9f0 schema:affiliation https://www.grid.ac/institutes/grid.415335.5
74 schema:familyName Roberts
75 schema:givenName Adam
76 rdf:type schema:Person
77 N401d501ef5244c13aaccfdb47b28c3ea rdf:first sg:person.01123267045.93
78 rdf:rest N38b66a4934a34cd2ad78fd70b112d0f3
79 N44b5986070bb42119bb0b848b614fc94 schema:name Ipswich Research Institute, Ipswich, QLD, Australia
80 rdf:type schema:Organization
81 N4f67a59f0fcd46eb8f8a47384137f85c rdf:first sg:person.01051662137.93
82 rdf:rest N34cb7fff3f094efab0a26fe2c7309dcf
83 N5ced31c17576452faf6bfbdb6d84025e schema:name dimensions_id
84 schema:value pub.1105454719
85 rdf:type schema:PropertyValue
86 N5d826d4007ba453984ab0647e3f5f43b rdf:first sg:person.01323317216.22
87 rdf:rest N32528bcf930f4217a37f31a318149a14
88 N707d4bf50d194d3e8b7c9b5feaf13f7d rdf:first sg:person.01052333026.79
89 rdf:rest N84ba27c0da83474aaa4b7514b9308172
90 N7f7f1b5e116e40a8a00e374409dc4392 schema:affiliation https://www.grid.ac/institutes/grid.1002.3
91 schema:familyName Gilfillan
92 schema:givenName Christopher
93 rdf:type schema:Person
94 N81ff66dbca2a4f3f953e05f91764997f rdf:first N9335a0eabab84e22a6d0cd6a97b89502
95 rdf:rest Nea49511a78e8464b9a5cd06ed03d7c8b
96 N84ba27c0da83474aaa4b7514b9308172 rdf:first N2c8a4c3d0ac643fab4b1cfd5f32dcac7
97 rdf:rest N303a87b1a0944f95bc715c642ca843c7
98 N9335a0eabab84e22a6d0cd6a97b89502 schema:affiliation N1f201c7333b444b79453bf6d3e4981f2
99 schema:familyName Oldfield
100 schema:givenName Geoffrey S.
101 rdf:type schema:Person
102 Nb3e6cfd1c1594f3fa2167cc7c4ccc8df schema:volumeNumber 61
103 rdf:type schema:PublicationVolume
104 Nb40de77ea9074cbf8e4d2a5b474f4e24 rdf:first N3ebd7f5d1f3d4b2b9b9e3ea594e8d9f0
105 rdf:rest N401d501ef5244c13aaccfdb47b28c3ea
106 Nbfa2c6b101634ab2a2d25d8fd4abe26d schema:name doi
107 schema:value 10.1007/s00125-018-4677-0
108 rdf:type schema:PropertyValue
109 Nc627e33c26e44e1094a36768638096da rdf:first N30ad39668f714e569948414d43c7e404
110 rdf:rest N5d826d4007ba453984ab0647e3f5f43b
111 Ncf0dbbb0088f46a3a38a9d884a72f47a schema:issueNumber 9
112 rdf:type schema:PublicationIssue
113 Nd9f65af247c94be292ac8564e38defbf schema:name Australian Clinical Research Network, Maroubra, NSW, Australia
114 rdf:type schema:Organization
115 Ndf3b5ab39be74d72b1a0e96db6a91d89 schema:name nlm_unique_id
116 schema:value 0006777
117 rdf:type schema:PropertyValue
118 Nea49511a78e8464b9a5cd06ed03d7c8b rdf:first sg:person.01325205777.93
119 rdf:rest Nb40de77ea9074cbf8e4d2a5b474f4e24
120 Nf9f8cb595d534931855c34c90502b7fc rdf:first N7f7f1b5e116e40a8a00e374409dc4392
121 rdf:rest N707d4bf50d194d3e8b7c9b5feaf13f7d
122 Nfaa313501f06445191b285ff59dfcb7f schema:affiliation N44b5986070bb42119bb0b848b614fc94
123 schema:familyName Nathow
124 schema:givenName Thomas
125 rdf:type schema:Person
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 sg:journal.1001482 schema:issn 0012-186X
133 1432-0428
134 schema:name Diabetologia
135 rdf:type schema:Periodical
136 sg:person.01007616347.53 schema:affiliation https://www.grid.ac/institutes/grid.1003.2
137 schema:familyName de Looze
138 schema:givenName Ferdinandus J.
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007616347.53
140 rdf:type schema:Person
141 sg:person.01051662137.93 schema:affiliation https://www.grid.ac/institutes/grid.1008.9
142 schema:familyName Proietto
143 schema:givenName Joseph
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051662137.93
145 rdf:type schema:Person
146 sg:person.01052333026.79 schema:affiliation https://www.grid.ac/institutes/grid.1003.2
147 schema:familyName Griffin
148 schema:givenName Paul
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052333026.79
150 rdf:type schema:Person
151 sg:person.011171643560.46 schema:affiliation https://www.grid.ac/institutes/grid.476821.e
152 schema:familyName Kim
153 schema:givenName Dennis
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011171643560.46
155 rdf:type schema:Person
156 sg:person.01123267045.93 schema:affiliation https://www.grid.ac/institutes/grid.489043.2
157 schema:familyName Stuckey
158 schema:givenName Bronwyn G. A.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123267045.93
160 rdf:type schema:Person
161 sg:person.012621644022.25 schema:affiliation https://www.grid.ac/institutes/grid.413249.9
162 schema:familyName Yue
163 schema:givenName Dennis
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012621644022.25
165 rdf:type schema:Person
166 sg:person.01323317216.22 schema:affiliation https://www.grid.ac/institutes/grid.1051.5
167 schema:familyName Cohen
168 schema:givenName Neale D.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323317216.22
170 rdf:type schema:Person
171 sg:person.01325205777.93 schema:affiliation N0214cbad49f14eb1b6a458c1510e62fb
172 schema:familyName O’Neal
173 schema:givenName David N.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325205777.93
175 rdf:type schema:Person
176 sg:person.014420273662.55 schema:affiliation https://www.grid.ac/institutes/grid.476821.e
177 schema:familyName Taylor
178 schema:givenName Kristin
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014420273662.55
180 rdf:type schema:Person
181 sg:person.0576721137.94 schema:affiliation https://www.grid.ac/institutes/grid.476821.e
182 schema:familyName Zhuang
183 schema:givenName Dongliang
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576721137.94
185 rdf:type schema:Person
186 sg:person.0722737420.82 schema:affiliation https://www.grid.ac/institutes/grid.476821.e
187 schema:familyName Malloy
188 schema:givenName Jaret
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722737420.82
190 rdf:type schema:Person
191 https://doi.org/10.1002/oby.20356 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016812973
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0140-6736(17)33102-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099600682
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1021/bi049172p schema:sameAs https://app.dimensions.ai/details/publication/pub.1055199593
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1073/pnas.162349799 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042637853
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1111/dom.12457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005353201
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1111/dom.12928 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084211943
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1111/dom.13021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085714853
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1124/jpet.117.246272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101276712
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1677/jme.1.02165 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041136245
208 rdf:type schema:CreativeWork
209 https://doi.org/10.3389/fendo.2013.00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001416282
210 rdf:type schema:CreativeWork
211 https://www.grid.ac/institutes/grid.1002.3 schema:alternateName Monash University
212 schema:name Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia
213 Emeritus Research, Malvern East, VIC, Australia
214 Institution for Rehabilitation Research, Monash University, Clayton, VIC, Australia
215 rdf:type schema:Organization
216 https://www.grid.ac/institutes/grid.1003.2 schema:alternateName University of Queensland
217 schema:name AusTrials Pty Ltd, Sherwood, QLD, Australia
218 Discipline of General Practice, Faculty of Medicine, University of Queensland, Herston, QLD, Australia
219 Faculty of Medicine, University of Queensland, Herston, QLD, Australia
220 Mater Health Services, South Brisbane, QLD, Australia
221 Q-Pharm Pty Ltd, Herston, QLD, Australia
222 QIMR Berghofer Medical Research Institute, Herston, QLD, Australia
223 rdf:type schema:Organization
224 https://www.grid.ac/institutes/grid.1008.9 schema:alternateName University of Melbourne
225 schema:name Department of Medicine (Austin Health), University of Melbourne, Heidelberg, VIC, Australia
226 rdf:type schema:Organization
227 https://www.grid.ac/institutes/grid.1051.5 schema:alternateName Baker IDI Heart and Diabetes Institute
228 schema:name Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.413249.9 schema:alternateName Royal Prince Alfred Hospital
231 schema:name Royal Prince Alfred Hospital, Camperdown, NSW, Australia
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.415335.5 schema:alternateName Geelong Hospital
234 schema:name University Hospital Geelong, Geelong, VIC, Australia
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.476821.e schema:alternateName Zafgen (United States)
237 schema:name Zafgen, Inc., 175 Portland St, 4th Floor, 02114, Boston, MA, USA
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.489043.2 schema:alternateName Keogh Institute for Medical Research
240 schema:name Keogh Institute for Medical Research, University of Western Australia, Nedlands, WA, Australia
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...